Pfizer, Teva autoimmune, neurology, generics news

Teva received rights to launch a generic version of Pfizer's Celebrex celecoxib for pain and autoimmune indications after the parties settled a 2013 suit under which Pfizer alleged that an ANDA from Teva seeking to market the generic infringed reissued U.S. Patent No. RE44048. Pfizer said that the settlement includes a license allowing Teva to launch its generic in the U.S. in December 2014 and that under certain conditions Pfizer would be eligible to receive royalties through Dec. 2, 2015, which is when the '048 patent expires. Pfizer said that additional terms of the settlement are confidential, and Teva could not be reached for comment. ...